StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Tuesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ EGRX opened at $0.50 on Tuesday. The stock’s 50-day moving average is $0.69 and its 200 day moving average is $2.93. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $6.81.

Institutional Trading of Eagle Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Mackenzie Financial Corp bought a new position in shares of Eagle Pharmaceuticals during the second quarter valued at about $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Eagle Pharmaceuticals during the 2nd quarter valued at about $65,000. Fidelis Capital Partners LLC bought a new position in Eagle Pharmaceuticals during the 2nd quarter worth approximately $71,000. Vanguard Personalized Indexing Management LLC purchased a new position in Eagle Pharmaceuticals in the 2nd quarter worth approximately $76,000. Finally, Creative Planning bought a new stake in Eagle Pharmaceuticals in the third quarter valued at approximately $59,000. 85.36% of the stock is owned by institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.